{
    "nctId": "NCT05957042",
    "briefTitle": "Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).",
    "officialTitle": "Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Contrast Enhanced Ultrasound",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Volume of mass on as visualized on contrast (Lumason) enhanced ultrasound at Baseline",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Willingness and ability to sign and date the study-specific informed consent form.\n* Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study.\n* Age greater than 18yo.\n* Stage I-III TNBC or stage IV TNBC with intact breast primary.\n* Planned combined ICI therapy as per SoC by treating oncologist.\n\nExclusion Criteria:\n\n* Other clinical trials are not excluded but participation must be cleared with the other clinical trial PIs.\n* Patients not suitable to undergo contrast enhanced ultrasound (i.e., pregnant women, known allergy to eggs, or a past allergic reaction to sonographic contrast or its components, such as polyethylene glycol (PEG))",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}